Page last updated: 2024-08-05 13:17:27
hydroxy seco-steroid
null
ChEBI ID: 36853
Members (7)
| Member | Definition | Role |
|---|---|---|
| 1,23,25-trihydroxyvitamin d3 | A hydroxycalciol that consists of vitamin D3 (calciol) bearing additional hydroxy substituents at positions 1, 23 and 25 (with 1alpha,23S-configuration). An intermediate in the degradation pathway of 1alpha,25-(OH)2D3. | 1alpha,23(S),25-trihydroxyvitamin D3 |
| calcipotriene | A seco-cholestane that is 26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene carrying additional hydroxy substituents at positions 1, 3 and 24. It is used (as its hydrate) in combination with betamethasone dipropionate, a corticosteroid, for the topical treatment of plaque psoriasis in adult patients. | calcipotriol |
| cholecalciferol | A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone. | calciol |
| mogrol | A tetracyclic triterpenoid that is cucurbitadienol in which the side-chain double bond (position 24-25) has undergone formal oxidation to introduce hydroxy groups at positions 24 and 25 (the 24R stereoisomer). It is a biometabolite of mogrosides found in Siraitia grosvenorii. | mogrol |
| paricalcitol | paricalcitol | |
| previtamin d(3) | A hydroxy seco-steroid which is an intermediate in the production of vitamin D3 in human skin. | previtamin D3 |
| vitamin d 2 | A vitamin D supplement and has been isolated from alfalfa. | vitamin D2 |
Research
Studies (10,313)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3,463 (33.58) | 18.7374 |
| 1990's | 1,023 (9.92) | 18.2507 |
| 2000's | 1,517 (14.71) | 29.6817 |
| 2010's | 3,173 (30.77) | 24.3611 |
| 2020's | 1,137 (11.02) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,836 (15.22%) | 5.53% |
| Reviews | 1,217 (10.09%) | 6.00% |
| Case Studies | 488 (4.04%) | 4.05% |
| Observational | 68 (0.56%) | 0.25% |
| Other | 8,457 (70.09%) | 84.16% |